Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Innate and myeloid checkpoint antibodies act on macrophages, natural killer (NK) cells and other innate immune cells. Magrolimab blocks CD47, which binds signal-regulatory protein alpha (SIRPĪ±) on macrophages and suppresses phagocytosis of target cells. Monalizumab targets the inhibitory NK cell receptor NKG2A, which recognizes HLA-E on tumor cells. Axatilimab and cabiralizumab bind colony-stimulating factor 1 receptor (CSF1R) and are used to study tumor-associated macrophages in vitro and in vivo. Further antibodies target sialic acid-binding Ig-like lectins (Siglecs), TREM receptors and the activating receptor NKG2D.
Synonyms: ELA-026
Ipsoprubart is a humanized IgG1Īŗ antibody that selectively targets SIRPa/CD172a, a critical receptor involved in immune system regulation. This antibody is instrumental in exploring immune checkpoint mechanisms and the modulation of immune responses. Research applications include studies on macrophage polarization and cancer immunotherapy, facilitating advancements in personalized medicine and immunomodulation strategies.
Out of stock
All 3 sizes
Lifonebart is a humanized monoclonal antibody that specifically inhibits TREM2 (triggering receptor expressed on myeloid cells 2). This antibody isotype is human IgG1Īŗ and is suitable for research applications investigating the immune response and neuroinflammation. Lifonebart serves as a crucial tool for studying the role of TREM2 in various pathological conditions, including neurodegenerative diseases.
Out of stock
All 3 sizes
Azerutamig is a bispecific monoclonal antibody that simultaneously targets KLRK1 (NKG2D) and ERBB2 (HER2). Based on a scFv-Fc architecture, this antibody facilitates immune cell redirection and cytotoxicity toward HER2-positive tumor cells expressing NKG2D ligands. Azerutamig is suitable for research in cancer immunotherapy and bispecific antibody engineering..
Synonyms: IBI-188
Letaplimab (IBI-188) is a human IgG4 monoclonal antibody targeting CD47, a protein frequently overexpressed on the surface of cancer cells and acting as a ligand for signal regulatory protein alpha (SIRPĪ±). By binding to CD47, Letaplimab disrupts its interaction with SIRPĪ±, thereby enhancing the phagocytosis of tumor cells. This mechanism positions Letaplimab as a promising therapeutic agent in the field of oncology, particularly for the treatment of cancers characterized by high CD47 expression.
STI-6643 is a fully human IgG4 monoclonal antibody specifically targeting CD47. It demonstrates significant anti-tumor efficacy while exhibiting minimal toxicity to red blood cells and lymphocytes. For isotype control, Human IgG4 (S228P) kappa, Isotype Control is recommended. This specificity and safety profile make STI-6643 a valuable tool for research in cancer immunotherapy.
Synonyms: RG 7155; RO 5509554
Emactuzumab (RG 7155) is a highly specific monoclonal antibody designed to inhibit the activation of the colony-stimulating factor 1 receptor (CSF1R). It exhibits a high affinity for CSF-1R with a dissociation constant (Ki) of 0.2 nM, effectively blocking CSF-1R dimerization. This antibody is primarily utilized in research focused on various diseases, including diffuse-type tenosynovial giant cell tumor (dt-GCT). Emactuzumab serves as a crucial tool for elucidating the role of CSF1R in disease pathology and for the development of therapeutic strategies targeting this receptor.
The Anti-SIRPg/CD172g Antibody (KWAR23) is a recombinant human monoclonal antibody specifically targeting Signal-Regulatory Protein Gamma (SIRPG). This antibody binds with high affinity to SIRPG, a protein expressed on the surface of myeloid cells and involved in modulating immune responses. The Anti-SIRPg/CD172g Antibody (KWAR23) is ideal for use in research focusing on immune regulation, signal transduction pathways, and potential therapeutic interventions for diseases involving the immune system.
Lumistobart is a humanized IgG1Īŗ monoclonal antibody that specifically targets signal-regulatory protein alpha (SIRPA). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.
Synonyms: FSI-189; GS-0189
Epacmarstobart (FSI-189; GS-0189) is a chimeric humanized monoclonal antibody of the IgG1Īŗ subclass, specifically designed to target the mouse signal regulatory protein alpha (SIRPĪ±). This antibody facilitates research into the modulation of immune responses, particularly in models studying phagocytosis inhibition by SIRPĪ± signaling in macrophages and other phagocytic cells. Its humanized design minimizes immunogenicity, making it an ideal tool for prolonged studies in murine models.
Synonyms: NCI m972
Anti-Siglec-2 / CD22 (NCI m972) is a humanized monoclonal antibody specifically designed to target CD22, a member of the Siglec family of lectins predominantly expressed on B cells. This antibody shows potential as a novel therapeutic agent for the treatment of B-cell acute lymphoblastic leukemia (BCP-ALL), offering targeted intervention in the disease pathology.
Synonyms: BMS-986315
Zimistobart (BMS-986315) is a fully human IgG1 monoclonal antibody specifically designed to target NKG2A, a receptor involved in the modulation of immune responses. This antibody is particularly useful in research focused on non-small cell lung cancer (NSCLC), providing a valuable tool for studies aimed at understanding and potentially manipulating immune evasion mechanisms in cancer cells. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.
Synonyms: 5G-12
NC-318 (5G-12) is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Siglec-15/CD33L3. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, with a predicted molecular weight of 146.98 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.
AMG-820 is a fully human monoclonal antibody of the IgG2 isotype specifically designed to target CSF-1R (Colony Stimulating Factor 1 Receptor). This antibody effectively blocks the binding of its natural ligands, CSF1 and IL34, thereby inhibiting receptor activation induced by these ligands. For experimental control purposes, the Human IgG2 kappa, Isotype Control is recommended as a suitable isotype control for AMG-820. This product is essential for research focused on the modulation of CSF-1R activity, particularly in studies related to inflammation and cancer where CSF-1R plays a critical role.
Synonyms: Gensci-059
Gentulizumab (Gensci-059) is a humanized IgG4 monoclonal antibody specifically designed to target CD47. This antibody demonstrates robust binding affinity for CD47 across both human and monkey tissues, effectively disrupting the CD47-SIRPĪ± interaction. Such inhibition plays a critical role in modulating antitumor immunity, making Gentulizumab a potent agent for antitumor activity studies. For experimental control purposes, Human IgG4 (S228P) kappa serves as the appropriate isotype control for Gentulizumab.
Synonyms: SRF-231
Urabrelimab (SRF231) is a fully human monoclonal antibody targeting CD47. It effectively inhibits the interaction between CD47 and signal-regulatory protein alpha (SIRPĪ±), a critical pathway involved in evading phagocytosis by immune cells. This blockade can promote the engulfment and elimination of cancer cells, making it a valuable tool for oncology research.
ATG-031 is a humanized monoclonal antibody targeting CD24, designed to enhance the immune system's ability to combat cancer. By inhibiting CD24-mediated "don't eat me" signals, ATG-031 promotes macrophage-mediated phagocytosis, leading to the destruction of cancer cells. This antibody is applicable in research focused on both hematological malignancies and solid tumors, providing a valuable tool for studies aimed at understanding and potentially disrupting cancer cell survival mechanisms.
Atibuclimab is a chimeric monoclonal antibody targeting CD14, comprised of murine variable regions and human IgG4 Fc regions. This antibody is specifically designed for research purposes in amyotrophic lateral sclerosis (ALS). Atibuclimab effectively moderates lipopolysaccharide (LPS)-induced symptoms and robustly suppresses the release of proinflammatory cytokines induced by LPS. Concurrently, it moderately delays the secretion of anti-inflammatory cytokines, including soluble TNF receptor type I and IL-1 receptor antagonist, providing a distinct profile of cytokine regulation. This dual action makes Atibuclimab a valuable tool for investigating inflammatory pathways and their modulation in ALS research.
Synonyms: FPA 008; Anti-Human CSF1R Recombinant Antibody
Cabiralizumab (FPA 008) is a monoclonal antibody targeting CSF1R (Colony Stimulating Factor 1 Receptor), designed to modulate the immune system by enhancing T cell infiltration and promoting antitumor immune responses. This antibody effectively inhibits the activation of osteoclasts, thereby preventing bone destruction, making it a valuable tool in the study of rheumatoid arthritis. Additionally, Cabiralizumab has been utilized in combination with Nivolumab in the exploration of therapeutic strategies for lung cancer, highlighting its potential in oncology research settings.
Synonyms: CC-95251; BMS-986351
Anzurstobart (CC-95251; BMS-986351) is a fully human monoclonal antibody targeting SIRPĪ± with high affinity. This antibody effectively inhibits the interaction between CD47 and SIRPĪ±, a critical pathway that tumors exploit to evade immune destruction. By blocking this interaction, Anzurstobart enhances the phagocytic activity of macrophages, particularly in co-culture models of diffuse large B-cell lymphoma (DLBCL) when used in conjunction with Rituximab. This antibody is primarily researched for its therapeutic potential in both solid tumors and hematological malignancies, offering significant insights into immune checkpoint blockade strategies.
Safimestomig is a bispecific IgG4Īŗ antibody designed to target CD47 and CD274. For experimental control purposes, the recommended isotype control is Human IgG4 (S228P) kappa. This control is essential for validating the specificity and ensuring the accuracy of bioassays involving Safimestomig.
The Anti-NKG2D/CD314 Antibody (1D11) is a chimeric mouse monoclonal antibody of the IgG1, Īŗ subclass, specifically designed to target human NKG2D/CD314. This antibody selectively binds to the NKG2D receptor, a key player in immune cell activation. For accurate isotype control in experimental assays, it is recommended to use Mouse IgG1 kappa, Isotype Control. This antibody is ideal for use in research focused on immune response modulation and the study of diseases where NKG2D signaling is implicated.
Zovostotug is a monoclonal antibody that specifically targets human CD163, a member of the scavenger receptor cysteine-rich (SRCR) superfamily, type 1 M130. This antibody is designed for precision in binding to CD163, which is predominantly expressed on the surface of macrophages and is involved in the clearance and endocytosis of hemoglobin/haptoglobin complexes. Zovostotug is an essential tool for researchers studying macrophage activation, inflammation processes, and the resolution of tissue damage, making it ideal for applications in immunology and cellular biology.
KWAR23 is a monoclonal antibody targeting human Signal Regulatory Protein Alpha (SIRPĪ±). This antibody exhibits high affinity for SIRPĪ±, effectively inhibiting its interaction with CD47. KWAR23 has demonstrated potential in enhancing antitumor responses, particularly when used alongside tumor-opsonizing antibodies. It is primarily utilized in the study of cancer immunotherapy, offering a promising tool for investigating checkpoint blockade strategies and tumor immune evasion mechanisms.
VTX-1218 is a humanized IgG1 monoclonal antibody designed to specifically target VSIG4, a protein implicated in immune regulation. This antibody is engineered for high specificity and affinity, making it suitable for a variety of research applications aimed at studying immune response modulation and potential therapeutic interventions in conditions where VSIG4 is a critical factor.
Synonyms: ABC-008
Ulviprubart (ABC-008) is a monoclonal antibody engineered to target the KLRG1 receptor, facilitating the selective depletion of highly differentiated cytotoxic T cells. This antibody is particularly useful in research focused on inclusion body myositis (IBM), providing a critical tool for investigating the pathophysiological mechanisms and potential therapeutic interventions for this condition.
